Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

In line with the "We the UAE 2031" Vision, the summit focused on improving quality of life and advancing specialized care for ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as the drugmaker’s new chief executive officer.

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch ...

Takeda Healthcare Philippines, Inc. and Otsuka-Solar Philippines, Inc., with the support of the Embassy of Japan in the Ph ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who plans to retire in June next year.

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price over the last couple of years.

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...